CHINA PHARMA HOLDINGS, INC.
No enriched coverage for $CPHI in the last 7 days.
No SEC Form 4 filings for $CPHI in the last 30 days.
China Pharma Holdings, Inc. (NYSE American: CPHI) said it closed a registered direct offering of 2.5 million shares at $2.00 per share, raising $5.0 million in gross proceeds. The company plans to use net proceeds for working capital and general corporate purposes. FT Global Capital acted as placement agent.
CHINA PHARMA HOLDINGS, INC. (CPHI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 ea029892101ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 22, 2026 between China Pharma Holdings, Inc., a Nevada corporation (the “ Co
China Pharma Holdings, Inc. (CPHI) shares fell 75.99% to $1.96 after the company priced a registered direct offering of 2.5 million common shares at $2.00 each. The deal is expected to raise about $5 million in gross proceeds, to be used for working capital and general corporate purposes, with closing around July 23, 2026.
Recent CPHI coverage spans corporate actions and market movers.
The dilutive equity raise can pressure near-term valuation, but provides liquidity for operations.
This filing signals a new capital-raising or financing transaction structure, which can affect dilution, liquidity, and near-term trading risk.
The dilutive equity raise at a low price is the immediate driver of the sharp selloff.
Dilutive capital raise at a low price is likely to pressure near-term valuation and sentiment until proceeds and use of funds are clearer.
The stock’s extreme gap higher is the primary tradable signal, but the article provides no confirmed fundamental catalyst beyond management’s lack of explanation.
alphai scores every news story that mentions CPHI with an AI model for sentiment and relevance, and aggregates insider trades from CHINA PHARMA HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
China Pharma Holdings, Inc. (NYSE American: CPHI) said it closed a registered direct offering of 2.5 million shares at $2.00 per share, raising $5.0 million in gross proceeds. The company plans to use net proceeds for working capital and general corporate purposes. FT Global Capital acted as placement agent.
2 min readCHINA PHARMA HOLDINGS, INC. (CPHI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 ea029892101ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 22, 2026 between China Pharma Holdings, Inc., a Nevada corporation (the “ Co
3 min readChina Pharma Holdings, Inc. (CPHI) shares fell 75.99% to $1.96 after the company priced a registered direct offering of 2.5 million common shares at $2.00 each. The deal is expected to raise about $5 million in gross proceeds, to be used for working capital and general corporate purposes, with closing around July 23, 2026.
2 min readChina Pharma Holdings Inc (CPHI) shares fell about 69% after it announced a $5 million registered direct offering priced at $2 per share. The company plans to sell 2.5 million shares, expecting net proceeds for working capital and general corporate purposes. FT Global Capital is the placement agent, with closing on or about July 23, 2026.
3 min readBiotech stocks hit 52-week highs on July 21, 2026, tied to clinical-trial updates and upcoming earnings. China Pharma Holdings (CPHI) surged over 790% to $19.19. Xencor (XNCR) closed at $21.25, up 8%. Eton Pharmaceuticals (ETON) reached $43.20. 10x Genomics (TXG) closed at $47.20. Acadia Healthcare (ACHC) hit $35.65 intraday.
5 min readChina Pharma Holdings (NYSE:CPHI) shares surged after hours, rising 9.74% to $8.89 following an intraday gain of 694.12% to a $8.10 close, per Benzinga Pro. Volume hit 93.61M shares versus 4.39M average. After NYSE American contacted the firm, it said it was unaware of material developments. Market cap $328.23M.
2 min read
